Company · cromsource-d12b6eee

Cromsource

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. Cromsource. Companies, record cromsource-d12b6eee. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/cromsource-d12b6eee

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: Cromsource
Trials: 18
As lead sponsor: 0
As collaborator: 18
Recruiting: 1
Active, recruiting or not: 2
Completed: 12
Stopped early, withdrawn or suspended: 3
Posted results: 5
Trials by phase: Phase 1 4, Phase 2 7, Phase 3 1, Phase 4 1
Drugs its trials test: 11
Comparisons calculated in its trials: 4
First trial registered: 2010-11-30
Last update: 2026-06-26

Source ClinicalTrials.gov

Pipeline11

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	Recruiting	Targets	Mechanism	In Drugs and targets	Source
LEVOTHYROXINE	Phase 4	1	0	THRA, THRB	Thyroid hormone receptor agonist	https://conductscience.org/library/drugs/CHEMBL1624	Open Targets
LEVOTHYROXINE SODIUM	Phase 4	1	0	THRA, THRB	Thyroid hormone receptor agonist	https://conductscience.org/library/drugs/CHEMBL2103741	Open Targets
GIVINOSTAT	Phase 2/3	1	1	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	Histone deacetylase inhibitor	https://conductscience.org/library/drugs/CHEMBL1213492	Open Targets
EMAPALUMAB	Phase 2	1	0	IFNG	Interferon gamma inhibitor	https://conductscience.org/library/drugs/CHEMBL3989977	Open Targets
EVEROLIMUS	Phase 2	1	0	FKBP1A	FK506-binding protein 1A inhibitor	https://conductscience.org/library/drugs/CHEMBL1908360	Open Targets
RIFAXIMIN	Phase 2	1	0			https://conductscience.org/library/drugs/CHEMBL1617	Open Targets
TACROLIMUS	Phase 2	1	0	FKBP1A	FK506-binding protein 1A inhibitor	https://conductscience.org/library/drugs/CHEMBL3989887	Open Targets
VELMANASE ALFA	Phase 2	1	0			https://conductscience.org/library/drugs/CHEMBL4298010	Open Targets
FOSTEMSAVIR	Phase 1/2	1	0			https://conductscience.org/library/drugs/CHEMBL3301594	Open Targets
CENEGERMIN	Phase 1	2	0	NTRK1, NTRK2, NTRK3	Neurotrophic tyrosine kinase receptor agonist	https://conductscience.org/library/drugs/CHEMBL4297852	Open Targets

1 to 10 of 11

See all 11 pipeline

Trials18

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	Results first posted	Drugs	In Trials	Source
NCT06022263	STA363 in the Treatment of Lumbar Disc Herniation	Collaborator	Phase 1	Completed	Interventional	25	2023-07-25		LACTIC ACID	https://conductscience.org/library/trials/NCT06022263	ClinicalTrials.gov
NCT05943288	Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy	Collaborator		Completed	Observational	850	2023-04-25			https://conductscience.org/library/trials/NCT05943288	ClinicalTrials.gov
NCT05228184	Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)	Collaborator	Phase 4	Terminated	Interventional	34	2022-01-21	2026-05-29	LEVOTHYROXINE, LEVOTHYROXINE SODIUM	https://conductscience.org/library/trials/NCT05228184	ClinicalTrials.gov
NCT05214560	Prospective Clinical Evaluation of BD Spinal Needles	Collaborator		Completed	Observational	160	2022-02-14	2024-08-19		https://conductscience.org/library/trials/NCT05214560	ClinicalTrials.gov
NCT04765566	FLUENCY® PLUS in the Treatment of Peripheral Artery Disease	Collaborator		Completed	Observational	146	2021-02-05			https://conductscience.org/library/trials/NCT04765566	ClinicalTrials.gov
NCT04731298	Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.	Collaborator	Phase 2	Terminated	Interventional	2	2021-05-25	2023-12-28	EMAPALUMAB	https://conductscience.org/library/trials/NCT04731298	ClinicalTrials.gov
NCT04648280	Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance	Collaborator	Phase 1/2	Active, not recruiting	Interventional	60	2022-06-30		FOSTEMSAVIR	https://conductscience.org/library/trials/NCT04648280	ClinicalTrials.gov
NCT04171570	DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention	Collaborator	Not applicable	Completed	Interventional	1,309	2019-12-10			https://conductscience.org/library/trials/NCT04171570	ClinicalTrials.gov
NCT03836859	Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers	Collaborator	Phase 1	Completed	Interventional	30	2018-03-30	2020-06-11	CENEGERMIN	https://conductscience.org/library/trials/NCT03836859	ClinicalTrials.gov
NCT03537157	A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention	Collaborator	Phase 2	Terminated	Interventional	43	2017-11-16		RIFAXIMIN	https://conductscience.org/library/trials/NCT03537157	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Conditions19

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Alpha-Mannosidosis	1
Analgesia	1
Anesthesia	1
Colorectal Cancer	1
Congenital Hypothyroidism	1
Coronary Disease	1
Crohn Disease	1
Duchenne Muscular Dystrophy	1
Glaucoma	1
Graft Failure	1

1 to 10 of 19Source ClinicalTrials.gov

See all 19 conditions

Partners27

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Chiesi Farmaceutici S.p.A.	Industry	2	https://conductscience.org/library/companies/chiesi-farmaceutici-s-p-a-3a51b16c	ClinicalTrials.gov
Dompé Farmaceutici S.p.A	Industry	2	https://conductscience.org/library/companies/dompe-farmaceutici-s-p-a-cc5f30e3	ClinicalTrials.gov
ABF Pharmaceutical Services GmbH	Industry	1	https://conductscience.org/library/companies/abf-pharmaceutical-services-gmbh-3180cf10	ClinicalTrials.gov
Advancell - Advanced In Vitro Cell Technologies, S.A.	Industry	1	https://conductscience.org/library/companies/advancell-advanced-in-vitro-cell-technologies-s-a-c457a5a6	ClinicalTrials.gov
Alfasigma S.p.A.	Industry	1	https://conductscience.org/library/companies/alfasigma-s-p-a-2c44cb08	ClinicalTrials.gov
Antaros Medical	Industry	1	https://conductscience.org/library/companies/antaros-medical-88697937	ClinicalTrials.gov
Becton, Dickinson and Company	Industry	1	https://conductscience.org/library/companies/becton-dickinson-and-company-0f34c393	ClinicalTrials.gov
BioMérieux	Industry	1	https://conductscience.org/library/companies/biomerieux-ca89f211	ClinicalTrials.gov
C. R. Bard	Industry	1	https://conductscience.org/library/companies/c-r-bard-3daaeecc	ClinicalTrials.gov
Celerion	Industry	1	https://conductscience.org/library/companies/celerion-98954fc9	ClinicalTrials.gov

1 to 10 of 27

See all 27 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/cromsource-d12b6eee

GET https://conductscience.org/api/companies/v1/cromsource-d12b6eee/partners?page=2

API reference For AI assistants